195.16

0.63% -1.23

Becton Dickinson Co (BDX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Becton Dickinson Co stock is traded at $195.16, with a volume of 292.72K. It is down -0.63% in the last 24 hours and up +6.17% over the past month. Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

Previous Close:

$196.39

Open:

$194.77

24h Volume:

292.72K

Relative Volume:

0.21

Market Cap:

$53.16B

Revenue:

$21.37B

Net Income/Loss:

$1.41B

P/E Ratio:

49.49

EPS:

3.9437

Net Cash Flow:

$3.07B

1W Performance:

+0.70%

1M Performance:

+6.17%

6M Performance:

+29.92%

1Y Performance:

+4.34%

1-Day Range:

$194.57

$196.16

1-Week Range:

$191.72

$200.47

52-Week Range:

$140.11

$213.08

Becton Dickinson Co Stock (BDX) Company Profile

Name

Becton Dickinson Co

Sector

Healthcare (1053)

Industry

Medical Instruments & Supplies (51)

Phone

(201) 847-6800

Address

ONE BECTON DR, FRANKLIN LAKES

Employee

72,000

Twitter

@BDandCo

Next Earnings Date

2026-11-05

Latest SEC Filings

BDX's Discussions on Twitter

Compare BDX vs ISRG, RMD, ALC, MDLN

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDX Becton Dickinson Co	195.16	53.16B	21.37B	1.41B	3.07B	3.9437
ISRG Intuitive Surgical Inc	446.85	157.86B	11.03B	3.16B	3.22B	8.7251
RMD Resmed Inc	250.74	35.26B	5.54B	1.52B	1.74B	10.37
ALC Alcon Inc	69.68	33.68B	10.63B	819.00M	1.59B	1.6577
MDLN Medline Inc	33.17	29.11B	29.14B	1.07B	1.05B	1.1956

Becton Dickinson Co Stock (BDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-26	Initiated	Wolfe Research	Outperform
Jul-28-26	Initiated	UBS	Buy
May-04-26	Resumed	Evercore ISI	Outperform
Apr-10-26	Resumed	Goldman	Neutral
Feb-10-26	Resumed	Barclays	Overweight
Feb-03-26	Resumed	Citigroup	Buy
Sep-25-25	Initiated	RBC Capital Mkts	Sector Perform
May-22-25	Downgrade	Citigroup	Buy → Neutral
May-02-25	Downgrade	Goldman	Buy → Neutral
May-02-25	Downgrade	Piper Sandler	Overweight → Neutral
May-02-25	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-25	Downgrade	BofA Securities	Buy → Neutral
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight
May-01-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-01-24	Upgrade	Citigroup	Neutral → Buy
May-30-24	Initiated	Goldman	Buy
Jul-24-23	Upgrade	Raymond James	Mkt Perform → Outperform
May-30-23	Resumed	Morgan Stanley	Overweight
May-05-23	Upgrade	Piper Sandler	Neutral → Overweight
Apr-12-23	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Jan-03-23	Upgrade	BofA Securities	Neutral → Buy
Dec-12-22	Upgrade	Citigroup	Sell → Neutral
Jul-11-22	Downgrade	Citigroup	Neutral → Sell
Jun-24-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-18-22	Resumed	Raymond James	Mkt Perform
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Downgrade	Piper Sandler	Overweight → Neutral
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
May-25-21	Initiated	Barclays	Equal Weight
Dec-15-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-15-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Jul-09-20	Upgrade	Barclays	Equal Weight → Overweight
Jun-01-20	Resumed	Goldman	Buy
Mar-05-20	Initiated	Citigroup	Neutral
Feb-07-20	Downgrade	Cowen	Outperform → Market Perform
Feb-07-20	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Feb-07-20	Downgrade	Raymond James	Strong Buy → Outperform
Feb-06-20	Downgrade	Cowen	Outperform → Market Perform
Jan-08-20	Downgrade	Barclays	Overweight → Equal Weight
May-13-19	Upgrade	Barclays	Equal Weight → Overweight
Dec-07-18	Initiated	Deutsche Bank	Buy
Oct-16-18	Initiated	Barclays	Equal Weight
Jun-21-18	Upgrade	JP Morgan	Neutral → Overweight
Apr-10-18	Upgrade	Citigroup	Neutral → Buy
Jan-19-18	Resumed	BofA/Merrill	Buy
Jan-05-18	Upgrade	Citigroup	Sell → Neutral
Jan-05-18	Initiated	KeyBanc Capital Mkts	Overweight
Jan-03-18	Initiated	Evercore ISI	Outperform
Dec-29-17	Reiterated	Deutsche Bank	Buy

View All

Becton Dickinson Co Stock (BDX) Latest News

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

Oct 26, 2026

Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures? - Zacks Investment Research

Oct 26, 2026

Oct 25, 2026

Becton Dickinson appoints Ferass Abuzaina as worldwide president of Surgery - scanx.trade

Oct 25, 2026

Oct 23, 2026

ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock? - Zacks Investment Research

Oct 23, 2026

BECTON, DICKINSON AND COMPANY (4BDX.TI) latest stock news and headlines - Yahoo Finance Australia

Oct 23, 2026

Oct 22, 2026